![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 5 of 5. This is the beginning of the thread.
Posted by steve552 on October 3, 2002, at 18:10:24
I've heard that Lilly will be coming out with a new dual action antidepressant which it cliams to be superior to Effexor. Does anyone have any addition info? I don't know of its name but it is suppose to be out next year.
Posted by JLM on October 3, 2002, at 18:17:30
In reply to New Lilly drug?, posted by steve552 on October 3, 2002, at 18:10:24
> I've heard that Lilly will be coming out with a new dual action antidepressant which it cliams to be superior to Effexor. Does anyone have any addition info? I don't know of its name but it is suppose to be out next year.
Its called Cymbalta. Google search it :)Lilly Antidepressant, Cymbalta, Gets FDA Approvable Letter
Followup to Prozac expected on market soon
Sept. 16, 2002 -- Eli Lilly and Co., maker of the onetime blockbuster antidepressant Prozac, said it has received an approvable letter from the Food and Drug Administration for its new antidepressant Cymbalta.An approvable letter from the FDA indicates the drug has passed most of the regulator's requirements. The drug company said Monday that it expects to receive final approval when it resolves labeling and outstanding manufacturing issues.
Lilly submitted a new drug application for Cymbalta in November 2001 along with data from five placebo-controlled depression studies and an open label safety study.
More than 3,000 patients have taken Cymbalta in clinical trials.
Lilly says the data suggest that 60 milligrams of Cymbalta, taken once daily, relieve symptoms of depression such as low mood, anxiety and physical symptoms such as aches and pains.
In fact, Lilly says, Cymbalta is superior to Prozac in that it affects two neurotransmitters involved in depression -- serotonin and norepinephrine. Other antidepressants, including Prozac, affect only serotonin, Lilly said. Researchers believe an imbalance of the two transmitters may explain the physical and emotional symptoms that depressed patients often endure, the company said.
Posted by jrbecker on October 4, 2002, at 12:33:06
In reply to Re: New Lilly drug?, posted by JLM on October 3, 2002, at 18:17:30
Lilly's also coming out this year with another NE moulating drug - Atomoxetine. This is supposed to be a softer form of treatment for ADHD symptoms and the like in comparison to stimulants. Some are already affirming it will also have a role in AD augmentation.
Posted by SLS on October 4, 2002, at 18:54:32
In reply to Re: New Lilly drug?, posted by jrbecker on October 4, 2002, at 12:33:06
> Lilly's also coming out this year with another NE moulating drug - Atomoxetine. This is supposed to be a softer form of treatment for ADHD symptoms and the like in comparison to stimulants. Some are already affirming it will also have a role in AD augmentation.
Hi Jennifer!I hope things have been great with you.
My doctor is considering atomoxetine for me in the future as an antidepressant. I'm currently trying to build around Nardil and Lamictal. I will probably be adding desipramine next, but I don't have any great expectations for it since I've been on similar combinations in the past.
The main "selling point" to duloxetine over Effexor is that the ratio of NE to 5-HT reuptake inhibition for duloxetine is closer to 1:1.
See 'ya.
- Scott
Posted by BarbaraCat on October 5, 2002, at 1:40:25
In reply to Re: New Lilly drug?, posted by JLM on October 3, 2002, at 18:17:30
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.